이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

PHASES: Provision of HIV Treatment at ATN Sites: An Evaluation for Stakeholders

2017년 2월 27일 업데이트: University of North Carolina, Chapel Hill
This is an observational study involving retrospective and prospective medical record review covering a total maximum of 104 weeks (24 months) per subject. An Audio Computer- Assisted Self-Interview (ACASI) at study entry will assess demographic and psychosocial variables of study subjects. Data will also be collected to assess clinic level variables. Definitions of engagement, prescription of antiretroviral therapy (ART), and viral suppression in the Continuum of Care (CoC) will utilize common definitions including those by U.S. Department of Health and Human Services (DHHS) and Health Resources and Services Administration (HRSA) HIV/AIDS Bureau (HAB). Data will be collected in a large, simple trial design manner to provide all elements for both the primary and secondary outcomes.

연구 개요

상태

완전한

정황

상세 설명

This is an observational study involving retrospective and prospective medical record review covering a total maximum of 104 weeks (24 months) per subject. Behavioral data will be collected via ACASI at study entry to assess demographic and psychosocial variables of study subjects. All other data (biomedical, ART, healthcare utilization) at subsequent study visits will be collected via medical record abstraction. Information about missed visits as well as other healthcare utilization data can be abstracted from electronic appointment systems or other electronic systems at the clinical sites. Subject data will be abstracted from medical records for up to a maximum 26 weeks prior to the baseline study visit, as well as up to a maximum 78 weeks after the baseline study visit or through January 31, 2017, whichever occurs first, for a total maximum of 104 weeks or two years per subject. Data will also be collected from each Adolescent Medicine Trials Unit to assess clinic level variables at baseline (within 30 days of protocol registration) and 48 and 96 weeks after baseline. Definitions of engagement, prescription of antiretroviral therapy (ART), and viral suppression in the Continuum of Care (CoC) will utilize common definitions including those by U.S. Department of Health and Human Services (DHHS) and Health Resources and Services Administration (HRSA) HIV/AIDS Bureau (HAB). Data will be collected in a large, simple trial design manner to provide all elements for both the primary and secondary outcomes.

연구 유형

관찰

등록 (실제)

924

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • California
      • Aurora, California, 미국, 80045
        • University of Colorado/The Children's Hospital
      • Los Angeles, California, 미국, 90027
        • Children's Hopsital of Los Angeles
    • District of Columbia
      • Washington, District of Columbia, 미국, 20010
        • Children's Hospital National Medical Center
    • Florida
      • Miami, Florida, 미국, 33101
        • University of Miami School of Medicine
      • Tampa, Florida, 미국, 33606
        • University Of South Florida
    • Illinois
      • Chicago, Illinois, 미국, 60612
        • Stroger Hospital of Cook County
    • Louisiana
      • New Orleans, Louisiana, 미국, 70112
        • Tulane University Health Sciences Center
    • Maryland
      • Baltimore, Maryland, 미국, 21287
        • Johns Hopkins University
    • Massachusetts
      • Boston, Massachusetts, 미국, 02215
        • Fenway Institute
    • Michigan
      • Detroit, Michigan, 미국, 48201
        • Children's Hospital of Michigan
    • New York
      • Bronx, New York, 미국, 10467
        • Montefiore Medical Center
    • Pennsylvania
      • Philadelphia, Pennsylvania, 미국, 19104
        • Children's Hospital of Philadelphia
    • Tennessee
      • Memphis, Tennessee, 미국, 38105
        • St. Jude Children's Research Hospital
    • Texas
      • Houston, Texas, 미국, 77030
        • Baylor College of Medicine/Texas Children's Hospital

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

13년 (어린이, 성인)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

샘플링 방법

비확률 샘플

연구 인구

  1. Behaviorally-infected, HIV-positive adolescents and young adults who are currently receiving or plan to receive their medical care at any clinical site that is part of the AMTU;
  2. Ages 13 through 24, inclusive, at the Baseline visit;
  3. Males and females;
  4. Ability to understand spoken English; and
  5. Ability for the AMTU staff to access the subject's medical records for a maximum of 78 weeks after enrollment or through February 2017, whichever occurs first.

설명

Inclusion Criteria:

  • Laboratory evidence of HIV-1 infection per Centers for Disease Control and Prevention (CDC) Surveillance Case Definition for HIV Infection, 2014 (Section 1.1) http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6303a1.htm;
  • Behaviorally-acquired HIV after age 9 years;
  • Age 13 through 24 years, inclusive, at the baseline visit (Enrollment);
  • Planning to receive HIV medical care at an AMTU or at any clinical site that is part of the AMTU for the duration of study follow-up

    • If transition to an adult health care provider must occur during the course of study participation, continued AMTU staff accessibility to medical and appointment records;

  • Ability for the AMTU staff to access medical and appointment records for a maximum of 78 weeks after enrollment or through February 2017, whichever occurs first;
  • Ability to understand spoken English;
  • Willing and able to provide signed informed consent or assent;

NOTE: If consent/assent is obtained > 4 weeks prior to the enrollment date, reaffirmation of consent must be obtained prior to starting the Baseline visit.

-Parent or Legal Guardian permission, if applicable; and

In addition to all the criteria listed above, to be considered eligible for enrollment after August 31, 2015, an individual must also meet the following criterion.

-Must be considered either: (a) newly engaged in HIV medical care defined as no previous initial comprehensive HIV medical care visit with consent occurring before, at the time of, or within four weeks following that initial comprehensive visit; or (b) newly re-engaged in HIV medical care defined as attending the last medical appointment more than 52 weeks ago.

*NOTE: The initial HIV medical care appointment is defined as a routine HIV medical appointment where the adolescent attends with a medical provider authorized to prescribe medication.

This HIV medical appointment must be a non-emergency, routine condition-focused exam AND one or more of the following:

  • CD4, VL lab draw and/or review of these lab results;
  • Discussion around HIV ART options;
  • Primary and/or secondary HIV prevention education and counseling; or
  • Diagnosis and treatment of complications of HIV, and of AIDS-defining conditions.

Exclusion Criteria:

  • Presence of serious psychiatric symptoms (e.g., active hallucinations, thought disorder) that would impair the individual's ability to provide true informed consent or participate in the baseline ACASI*;
  • Visibly distraught (e.g., suicidal, homicidal, exhibiting violent behavior) at the time of consent or the baseline ACASI*; or
  • Intoxicated or under the influence of alcohol or other substances at the time of consent or the baseline ACASI*

    • NOTE: If consent/assent is obtained prior to the enrollment date, assessment for these exclusion criteria must be performed again prior to administration of the baseline ACASI (Enrollment). If any are present, the subject cannot be enrolled; do not administer the ACASI. Reassessment of eligibility and enrollment may take place at a later date per the discretion of the treating clinician.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
기간
The proportion of subjects engaged in care at Baseline, per subject year, as defined by the HRSA HAB measure
기간: Baseline
Baseline
The proportion of subjects engaged in care at Week 26, per subject year, as defined by the HRSA HAB measure
기간: Week 26
Week 26
The proportion of subjects engaged in care at Week 52, per subject year, as defined by the HRSA HAB measure
기간: Week 52
Week 52
The proportion of subjects engaged in care at Week 78, per subject year, as defined by the HRSA HAB measure
기간: Week 78
Week 78
The proportion of subjects engaged in care at Baseline, per subject year, as defined by the DHHS measure
기간: Baseline
Baseline
The proportion of subjects engaged in care at Week 26, per subject year, as defined by the DHHS measure
기간: Week 26
Week 26
The proportion of subjects engaged in care at Week 52, per subject year, as defined by the DHHS measure
기간: Week 52
Week 52
The proportion of subjects engaged in care at Week 78, per subject year, as defined by the DHHS measure
기간: Week 78
Week 78
The proportion of subjects prescribed antiretroviral therapy at Baseline per subject year
기간: Baseline
Baseline
The proportion of subjects prescribed antiretroviral therapy at Week 26 per subject year
기간: Week 26
Week 26
The proportion of subjects prescribed antiretroviral therapy at Week 52 per subject year
기간: Week 52
Week 52
The proportion of subjects prescribed antiretroviral therapy at Week 78 per subject year
기간: Week 78
Week 78
The proportion of subjects that have achieved viral suppression at Baseline per subject year
기간: Baseline
Baseline
The proportion of subjects that have achieved viral suppression at Week 26 per subject year
기간: Week 26
Week 26
The proportion of subjects that have achieved viral suppression at Week 52 per subject year
기간: Week 52
Week 52
The proportion of subjects that have achieved viral suppression at Week 78 per subject year
기간: Week 78
Week 78

2차 결과 측정

결과 측정
기간
The proportion of subjects with advanced HIV disease at time of first clinical visit defined as a CD4 count < 200 cells/mm3
기간: Baseline
Baseline
The incidence of STIs in the study population as an indicator of transmission risk at Baseline
기간: Baseline
Baseline
The incidence of STIs in the study population as an indicator of transmission risk at Week 26
기간: Week 26
Week 26
The incidence of STIs in the study population as an indicator of transmission risk at Week 52
기간: Week 52
Week 52
The incidence of STIs in the study population as an indicator of transmission risk at Week 78
기간: Week 78
Week 78
Number of subjects with mental health issues at Baseline
기간: Baseline
Baseline
Number of subjects engaging in substance use at Baseline
기간: Baseline
Baseline
Number of subjects engaging in sexual risk behaviors at Baseline
기간: Baseline
Baseline
ART adherence rate at Baseline
기간: Baseline
Baseline
Frequency of missed clinic visits at Baseline
기간: Baseline
Baseline
Frequency of missed clinic visits at Week 26
기간: Week 26
Week 26
Frequency of missed clinic visits at Week 52
기간: Week 52
Week 52
Frequency of missed clinic visits at Week 78
기간: Week 78
Week 78
Types of services available at each AMTU at Baseline
기간: Baseline
Baseline
Types of services available at each AMTU at 48 weeks after Baseline
기간: Week 48
Week 48
Types of services available at each AMTU at 96 weeks after Baseline
기간: Week 96
Week 96
Proportion of subjects notifying their sexual partners after learning their HIV status
기간: Baseline
Baseline
Timing of subjects notifying their partners after learning about their HIV status
기간: Baseline
Baseline
Proportion of subjects with whom partner notification was discussed
기간: Baseline
Baseline

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Bret Rudy, MD, NYU Langone Health

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

유용한 링크

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작

2015년 3월 1일

기본 완료 (실제)

2016년 2월 1일

연구 완료 (실제)

2016년 2월 1일

연구 등록 날짜

최초 제출

2015년 4월 2일

QC 기준을 충족하는 최초 제출

2015년 5월 5일

처음 게시됨 (추정)

2015년 5월 8일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2017년 2월 28일

QC 기준을 충족하는 마지막 업데이트 제출

2017년 2월 27일

마지막으로 확인됨

2016년 3월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • ATN 125

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

에이즈에 대한 임상 시험

3
구독하다